STOCKSGilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 BillionBy Martin BaccardaxJul 15, 2019 9:40 AM EDT
STOCKSGalapagos Soars After Rheumatoid Arthritis Drug Meets Primary EndpointBy Alexander NicollMar 29, 2019 11:06 AM EDT
STOCKSVertex Pharma jumps 14% after rival releases poor cystic fibrosis drug resultsBy Alexander NicollJun 29, 2018 3:27 PM EDT
STOCKSVertex pharma moves next-generation cystic fibrosis drugs into new clinical trialsBy Adam FeuersteinOct 25, 2016 5:03 PM EDT
STOCKSCelgene skips the placebo, fails drug development 101By Adam FeuersteinOct 19, 2016 7:28 AM EDT
STOCKSAstraZeneca, Gilead Drug License Deals Could Pinch AbbVie GrowthBy Adam FeuersteinDec 17, 2015 8:48 AM EST
STOCKSVertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective TreatmentsBy Adam FeuersteinOct 8, 2015 12:10 PM EDT
STOCKSCredit Suisse's 8 Pharmaceutical Stocks With 'Significant' UpsideBy Laurie KulikowskiAug 28, 2015 12:58 PM EDT
STOCKSGalapagos Receives a Rousing Welcome on Its First Day of TradingBy James RubinMay 14, 2015 6:27 PM EDT
VIDEOGalapagos Drug in Partnership With AbbVie Looks to Replace HUMIRABy Jill MalandrinoMay 14, 2015 3:51 PM EDT
